MDL-800
Based on 2 publication(s) in Google Scholar
MDL-800 is an allosteric and selective SIRT6 activator. MDL-800 increases SIRT6 deacetylation activity with an EC50 of 10.3 µM.
For research use only. We do not sell to patients.
- Purity: 99.11%
- CAS No.: 2275619-53-7
- Formula: C21H16BrCl2FN2O6S2
- Molecular Weight:626.30
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Glutamine Metabolism Compound Library
HY-L064
-
Targeted Diversity Library
HY-L099
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Activators Library
HY-L159
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) MDL-800
More
Biological Activity
|
SIRT6 10.3 μM (EC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ASPC1 | IC50 |
50.51 μM
Compound: MDL-800
|
Antiproliferative activity against human AsPC1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human AsPC1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32787077] |
| Bel-7402 | IC50 |
18.6 μM
Compound: 7a; MDL-800
|
Antiproliferative activity against human Bel-7402 cells
Antiproliferative activity against human Bel-7402 cells
|
[PMID: 34213345] |
| BXPC-3 | IC50 |
57.96 μM
Compound: MDL-800
|
Antiproliferative activity against human BxPC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human BxPC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32787077] |
| MIA PaCa-2 | IC50 |
55.65 μM
Compound: MDL-800
|
Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MIAPaCa2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32787077] |
| PANC-1 | IC50 |
35.19 μM
Compound: MDL-800
|
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 32787077] |
| PLC-PRF-5 | IC50 |
18.6 μM
Compound: 7a; MDL-800
|
Antiproliferative activity against human PLCPRF5 cells
Antiproliferative activity against human PLCPRF5 cells
|
[PMID: 34213345] |
MDL-800 potently activates SIRT6 at ~10 µM but shows no activity toward SIRT1, SIRT3, SIRT4, and HDAC1-11 at concentrations up to 50 or 100 µM. Although MDL-800 exhibits weak activity toward SIRT2, SIRT5, and SIRT7, the EC50 or IC50 values are greater than 100 µM, tenfold less than that against SIRT6[1].
MDL-800 directly activates SIRT6 deacetylation by increasing the binding affinities of acetylated substrates and cofactor as well as increasing the catalytic efficiency of SIRT6[1].
MDL-800 (1-1000 μM; 48 hours) decreases the proliferation of Bel7405, PLC/PRF/5, and Bel7402 cells with IC50s for cell growth (IC50-growth) of 23.3 μM, 18.6 μM, and 24.0 μM, respectively, and EC50s for cell death (EC50-death) of 90.4 μM, 87.0 μM, and 106.5 μM, respectively[1].
MDL-800 (0-50 μM; 24 and 48 hours) decreases both H3K9ac and H3K56ac at a concentration of 10 µM and shows a dose-dependent effect in Bel7405, PLC/PRF/5, and Bel7402 cells at 24 and 48 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Bel7405, PLC/PRF/5, and Bel7402 cells
-
Concentration:1, 10, 100 , 1000 μM
-
Incubation Time:48 hours
-
Result:Decreased the proliferation of Bel7405, PLC/PRF/5, and Bel7402 cells with IC50s of 23.3 μM, 18.6 μM, and 24.0 μM, respectively.
-
Cell Line:Bel7405, PLC/PRF/5, and Bel7402 cells
-
Concentration:0, 5, 10, 25, and 50 μM
-
Incubation Time:24 and 48 hours
-
Result:Decreased both H3K9ac and H3K56ac at a concentration of 10 µM and showed a dose-dependent effect in all three cell lines at 24 h and 48 h.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Six-week-old female BALB/c nude mice with Bel7405 xenograft tumor mode[1]
-
Dosage:50, 100, and 150 mg/kg
-
Administration:Intraperitoneal injection; over 2 weeks.
-
Result:Suppressed the growth of Bel7405 xenografts in a dose-dependent manner. Decreased tumor weight and size.
Chemical Information
-
CAS No. 2275619-53-7
-
Appearance Solid
-
Molecular Weight 626.30
-
Formula C21H16BrCl2FN2O6S2
-
Color White to off-white
-
SMILES
ClC1=CC(S(NC2=CC=C(S(NC3=CC(Br)=C(F)C=C3C)(=O)=O)C(C(OC)=O)=C2)(=O)=O)=CC(Cl)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
SIRT6 activation attenuates inflammatory-fibrogenic events, improves lung function and survival in experimental pulmonary fibrosis. [Abstract]2026 Aug;250(Pt 1):117940. PMID: 41916469 -
Aging Med (Milton)
Visualization of OPN-Targeted Self-Assembled Micelles Encapsulated With an SIRT6 Activator and Doped Indocyanine Green for Attenuating Vascular Aging. [Abstract]2025 Oct 26;8(5):383-397. PMID: 41180385
Solvent & Solubility
DMSO : 125 mg/mL (199.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5967 mL | 7.9834 mL | 15.9668 mL | 39.9170 mL |
| 5 mM | 0.3193 mL | 1.5967 mL | 3.1934 mL | 7.9834 mL | |
| 10 mM | 0.1597 mL | 0.7983 mL | 1.5967 mL | 3.9917 mL | |
| 15 mM | 0.1064 mL | 0.5322 mL | 1.0645 mL | 2.6611 mL | |
| 20 mM | 0.0798 mL | 0.3992 mL | 0.7983 mL | 1.9958 mL | |
| 25 mM | 0.0639 mL | 0.3193 mL | 0.6387 mL | 1.5967 mL | |
| 30 mM | 0.0532 mL | 0.2661 mL | 0.5322 mL | 1.3306 mL | |
| 40 mM | 0.0399 mL | 0.1996 mL | 0.3992 mL | 0.9979 mL | |
| 50 mM | 0.0319 mL | 0.1597 mL | 0.3193 mL | 0.7983 mL | |
| 60 mM | 0.0266 mL | 0.1331 mL | 0.2661 mL | 0.6653 mL | |
| 80 mM | 0.0200 mL | 0.0998 mL | 0.1996 mL | 0.4990 mL | |
| 100 mM | 0.0160 mL | 0.0798 mL | 0.1597 mL | 0.3992 mL |
MDL-800 Related Classifications
HY-119376 Related Classifications
Powered by Bioz